RTSN
Retension completes upsized IPO for hypertension drug RTN-001
Retension Pharmaceuticals raised $45.1 million net through an upsized IPO in October 2026 to fund clinical trials. Stock began trading on Nasdaq under the symbol RTSN on October 9.